



Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

May 30, 2019

BEDFORD, Mass.--(BUSINESS WIRE)--May 30, 2019-- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present and host investor meetings at the following conferences:

Jefferies 2019 Global Healthcare Conference

Date: Thursday, June 6, 2019
Presentation Time: 4:30 PM ET
Location: Grand Hyatt in New York, NY

Raymond James Life Sciences and MedTech Conference

Date: Tuesday, June 18, 2019
Presentation Time: 4:10 PM ET
Location: Lotte New York Palace in New York, NY

JMP Securities Life Sciences Conference

Date: Wednesday, June 19, 2019
Presentation Time: 9:30 AM ET
Location: The St. Regis in New York, NY

A live webcast of the presentations can be accessed by visiting the Investors section of the Company's website at investors.ocutx.com.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA®, is FDA-approved for the treatment of ocular pain following ophthalmic surgery. OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, an extended-delivery intracameral travoprost implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These intravitreal implants include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190530005119/en/>

Source: Ocular Therapeutix, Inc.

Investors

Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com

Media

Ocular Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com
or
Westwicke, an ICR Company
Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com